Search | Clinical Trials Finder

Conditions: Sickle Cell Disease, Priapism
Interventions: sildenafil, placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years to 45 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peyronie Disease
Interventions: Collagenase Clostridium Histolyticum, RestoreX, Sildenafil; Drug · Device
Lead sponsor: Charitable Union for the Research and Education of Peyronie's Disease; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Orem, Utah

Conditions: Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
Interventions: sorafenib tosylate, valproic acid, sildenafil citrate; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cystic Fibrosis
Interventions: Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Pulmonary Arterial Hypertension, Children
Interventions: Sildenafil citrate, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 10
States / cities: Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Torrance, California • Jacksonville, Florida

Conditions: Thalassemia, Hypertension, Pulmonary
Interventions: Sildenafil; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 7 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Oakland, California

Conditions: Female Sexual Arousal Disorder
Interventions: Sildenafil 100 mg, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Emphysema
Interventions: Sildenafil 20 MG, Placebo Oral Tablet, Pulse wave velocity, Carotid artery compliance and stiffness, Pressure wave reflection; Drug · Diagnostic Test
Lead sponsor: Eric A. Hoffman; Other
Eligibility: 21 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Lymphangioma
Interventions: Sildenafil; Drug
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 10 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521), Placebo, Sildenafil; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Aurora, Colorado • Columbus, Ohio • Providence, Rhode Island

Conditions: None Volunteer
Interventions: sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Erectile Dysfunction
Interventions: Sildenafil Cream, Placebo Cream, Penile Plethysmography (RigiScan); Drug · Device
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: San Diego, California • New Orleans, Louisiana • New York, New York

Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions: Sildenafil; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stroke
Interventions: sildenafil citrate, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cystic Fibrosis
Interventions: sildenafil, placebo; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions: Sildenafil (50 mg); Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
Interventions: sildenafil, placebo; Drug · Other
Lead sponsor: Marywood University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Traumatic Brain Injury
Interventions: Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI; Drug · Device · Other + 1 more
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions: Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Nintedanib, Placebo, Sildenafil; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • Stamford, Connecticut • Jacksonville, Florida + 13 more

Conditions: Traumatic Brain Injury, Mild Traumatic Brain Injury, Post-Concussion Syndrome
Interventions: Sildenafil Citrate; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumor
Interventions: Regorafenib, Sildenafil Citrate; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Lymphatic Malformations, Lymphatic Diseases
Interventions: Sildenafil 20 mg tablets, Placebo tablets (resembling Revatio); Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 10 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Chicago, Illinois

Search by objective public record fields.

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Blood Flow and Vascular Function in Cystic Fibrosis

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)

Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension

Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder

Smoking Cessation and Functional CT Assessment

A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations

Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.

Taste Test of a New Formulation of Sildenafil (Revatio)

Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED

Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

Sildenafil and Stroke Recovery

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

Does Sildenafil Increase Exercise Performance in Air Pollution?

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Cerebrovascular Reactivity in American Football Players

Study of Regorafenib and Sildenafil for Advanced Solid Tumors

Sildenafil for the Treatment of Lymphatic Malformations